Jiannan Yao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiannan Yao has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Yang Ge
Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
8 shared publications Guangyu An
Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
7 shared publications- Jian Liu
Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
6 shared publications Xiaona Fan
Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
6 shared publicationsLing Duan
Beijing Tiantan Hospital, Capital Medical University, Beijing, China
5 shared publications- Guangyu An
Department of Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
4 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Targeting enolase isoenzyme 2 enables precision glycolysis inhibition in VHL-mutant renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) exhibits glycolytic addiction due to VHL mutation, making it vulnerable to metabolic intervention. While conventional inhibitors targeting core housekeeping glycolytic enzymes show robust antitumor efficacy, their clinical use is limited by on-target systemic toxicity. Here, we identify enolase 2 (ENO2) as an isoform-specific glycolytic vulnerability specific to VHL-deficient ccRCC. Although ENO2 is physiologically redundant (compensated by ENO1) in normal glycolysis, it becomes essential for sustaining ccRCC malignancy via VHL loss-HIF2α-driven glycolytic flux. Targeting ENO2 specifically suppressed glycolysis in VHL-deficient ccRCC cells, reducing their malignancy and enhancing their response to axitinib, doxorubicin, and gemcitabine. Importantly, pharmacological ENO2 blockade displayed superior tumor selectivity compared to traditional glycolysis inhibitors, effectively eliminating VHL-deficient ccRCC cells while sparing VHL-intact normal and malignant cells, despite causing slightly weaker glycolytic suppression. Mechanistic investigations revealed that ENO2 ablation inactivated up to ~78% of VHL loss-induced oncogenic effectors, including a pleiotropic oncoprotein MDK, through dual modulation of lactate metabolism and interferon signaling. Collectively, this work reveals ENO2 as a genotype-specific metabolic dependency in ccRCC, thereby enabling precision glycolytic therapy. Our work also suggests that targeting physiologically redundant metabolic isoenzymes may offer a precision medicine strategy for cancers with defined genetic alterations.
- 14 July 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessTargeting enolase isoenzyme 2 enables precision glycolysis inhibition in VHL-mutant renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) exhibits glycolytic addiction due to VHL mutation, making it vulnerable to metabolic intervention. While conventional inhibitors targeting core housekeeping glycolytic enzymes show robust antitumor efficacy, their clinical use is limited by on-target systemic toxicity. Here, we identify enolase 2 (ENO2) as an isoform-specific glycolytic vulnerability specific to VHL-deficient ccRCC. Although ENO2 is physiologically redundant (compensated by ENO1) in normal glycolysis, it becomes essential for sustaining ccRCC malignancy via VHL loss-HIF2α-driven glycolytic flux. Targeting ENO2 specifically suppressed glycolysis in VHL-deficient ccRCC cells, reducing their malignancy and enhancing their response to axitinib, doxorubicin, and gemcitabine. Importantly, pharmacological ENO2 blockade displayed superior tumor selectivity compared to traditional glycolysis inhibitors, effectively eliminating VHL-deficient ccRCC cells while sparing VHL-intact normal and malignant cells, despite causing slightly weaker glycolytic suppression. Mechanistic investigations revealed that ENO2 ablation inactivated up to ~78% of VHL loss-induced oncogenic effectors, including a pleiotropic oncoprotein MDK, through dual modulation of lactate metabolism and interferon signaling. Collectively, this work reveals ENO2 as a genotype-specific metabolic dependency in ccRCC, thereby enabling precision glycolytic therapy. Our work also suggests that targeting physiologically redundant metabolic isoenzymes may offer a precision medicine strategy for cancers with defined genetic alterations.
- Open Access
- 7 August 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-17
Hypoxic stimulation of DCLK1 transcription and alternative-promoter switching fuels tumor malignancy in clear cell renal cell carcinoma
Alterations in the diversity and abundance of oncogenic gene transcripts are key factors driving tumor initiation and progression. DCLK1, an emerging cancer stem cell marker, is activated during tumorigenesis, triggering cancer stemness and metastasis. It produces long or short isoforms through selective usage of alternative promoters (α- or β-promoter). However, the mechanism mediating DCLK1 activation and choice of AP model in cancer remains unclear. Herein, we reveal that DCLK1 is significantly activated, with a concomitant alternative-promoter model switch (β-to-α) towards the long variants (isoform 1 and 2) in clear cell renal cell carcinoma (ccRCC). During tumorigenesis, the α-promoter is initiated with an improved probability from 31.6% to 61.1%, whereas the initiation probability of the β-promoter declined from 68.4% to 38.9%. Mechanistically, this alteration is mediated by a hypoxia-HIF2α-PLOD2 axis, which further activates β-catenin to selectively bind and activate the α-promoter. Our findings also showed that the hyperactivated PLOD2-DCLK1-L axis in ccRCC is correlated with a higher EMT signature and predicts an unfavorable prognosis in ccRCC patients, while disrupting this signaling by pharmacological targeting of DCLK1-L significantly attenuated cancer malignancy both in vitro and in vivo. These findings couple hypoxia signaling to oncogenic alternative switching and highlight DCLK1-L as a promising therapeutic target for hypoxic PLOD2-rich ccRCCs.
- 7 August 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-17
Open AccessHypoxic stimulation of DCLK1 transcription and alternative-promoter switching fuels tumor malignancy in clear cell renal cell carcinoma
Alterations in the diversity and abundance of oncogenic gene transcripts are key factors driving tumor initiation and progression. DCLK1, an emerging cancer stem cell marker, is activated during tumorigenesis, triggering cancer stemness and metastasis. It produces long or short isoforms through selective usage of alternative promoters (α- or β-promoter). However, the mechanism mediating DCLK1 activation and choice of AP model in cancer remains unclear. Herein, we reveal that DCLK1 is significantly activated, with a concomitant alternative-promoter model switch (β-to-α) towards the long variants (isoform 1 and 2) in clear cell renal cell carcinoma (ccRCC). During tumorigenesis, the α-promoter is initiated with an improved probability from 31.6% to 61.1%, whereas the initiation probability of the β-promoter declined from 68.4% to 38.9%. Mechanistically, this alteration is mediated by a hypoxia-HIF2α-PLOD2 axis, which further activates β-catenin to selectively bind and activate the α-promoter. Our findings also showed that the hyperactivated PLOD2-DCLK1-L axis in ccRCC is correlated with a higher EMT signature and predicts an unfavorable prognosis in ccRCC patients, while disrupting this signaling by pharmacological targeting of DCLK1-L significantly attenuated cancer malignancy both in vitro and in vivo. These findings couple hypoxia signaling to oncogenic alternative switching and highlight DCLK1-L as a promising therapeutic target for hypoxic PLOD2-rich ccRCCs.
- 8 May 2025
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 185, 106789
Restoration of A2M reduces drug resistance and malignancy in paclitaxel-resistant lung cancer cells
- 8 May 2025
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 185, 106789
Restoration of A2M reduces drug resistance and malignancy in paclitaxel-resistant lung cancer cells
- Open Access
- 15 May 2024
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 73 (7) , 1-19
GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration
Purpose: The variable responses to immunotherapy observed in gastric cancer (GC) patients can be attributed to the intricate nature of the tumor microenvironment. Glutathione (GSH) metabolism significantly influences the initiation and progression of gastric cancer. Consequently, targeting GSH metabolism holds promise for improving the effectiveness of Immune checkpoints inhibitors (ICIs). Methods: We investigated 16 genes related to GSH metabolism, sourced from the MSigDB database, using pan-cancer datasets from TCGA. The most representative prognosis-related gene was identified for further analysis. ScRNA-sequencing analysis was used to explore the tumor heterogeneity of GC, and the results were confirmed by Multiplex immunohistochemistry (mIHC). Results: Through DEGs, LASSO, univariate and multivariate Cox regression analyses, and survival analysis, we identified GGT5 as the hub gene in GSH metabolism with the potential to promote GC. Combining CIBERSORT, ssGSEA, and scRNA analysis, we constructed the immune architecture of GC. The subpopulations of T cells were isolated, revealing a strong association between GGT5 and memory CD8+ T cells. Furthermore, specimens from 10 GC patients receiving immunotherapy were collected. mIHC was used to assess the expression levels of GGT5 and memory CD8+ T cell markers. Our results established a positive correlation between GGT5 expression, the enrichment of memory CD8+ T cells, and a suboptimal response to immunotherapy. Conclusions: Our study identifies GGT5, a hub gene in GSH metabolism, as a potential therapeutic target for inhibiting the response to immunotherapy in GC patients. These findings offer new insights into strategies for optimizing immunotherapy of GC.
- 15 May 2024
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 73 (7) , 1-19
Open AccessGGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration
Purpose: The variable responses to immunotherapy observed in gastric cancer (GC) patients can be attributed to the intricate nature of the tumor microenvironment. Glutathione (GSH) metabolism significantly influences the initiation and progression of gastric cancer. Consequently, targeting GSH metabolism holds promise for improving the effectiveness of Immune checkpoints inhibitors (ICIs). Methods: We investigated 16 genes related to GSH metabolism, sourced from the MSigDB database, using pan-cancer datasets from TCGA. The most representative prognosis-related gene was identified for further analysis. ScRNA-sequencing analysis was used to explore the tumor heterogeneity of GC, and the results were confirmed by Multiplex immunohistochemistry (mIHC). Results: Through DEGs, LASSO, univariate and multivariate Cox regression analyses, and survival analysis, we identified GGT5 as the hub gene in GSH metabolism with the potential to promote GC. Combining CIBERSORT, ssGSEA, and scRNA analysis, we constructed the immune architecture of GC. The subpopulations of T cells were isolated, revealing a strong association between GGT5 and memory CD8+ T cells. Furthermore, specimens from 10 GC patients receiving immunotherapy were collected. mIHC was used to assess the expression levels of GGT5 and memory CD8+ T cell markers. Our results established a positive correlation between GGT5 expression, the enrichment of memory CD8+ T cells, and a suboptimal response to immunotherapy. Conclusions: Our study identifies GGT5, a hub gene in GSH metabolism, as a potential therapeutic target for inhibiting the response to immunotherapy in GC patients. These findings offer new insights into strategies for optimizing immunotherapy of GC.
- 13 July 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 675, 106-112
MTA1 localizes to the mitotic spindle apparatus and interacts with TPR in spindle assembly checkpoint regulation
- 13 July 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 675, 106-112
MTA1 localizes to the mitotic spindle apparatus and interacts with TPR in spindle assembly checkpoint regulation
- Open Access
- 2 June 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1076473
Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis
Introduction: Cutaneous adverse events are commonly reported immune-related adverse events (irAEs), some of which are serious or even life-threatening, and it is essential to study these specific cutaneous AEs to understand their characteristics and risk.Methods: We performed a meta-analysis of published clinical trials for immune checkpoint inhibitors (ICIs) to evaluate the incidence of cutaneous adverse events, using data from PubMed, Embase, and the Cochrane Library databases.Results: A total of 232 trials with 45,472 patients were involved. Results showed that anti-PD-1 and targeted therapy combinations were associated with higher risk for most of the selected cutaneous adverse events. In addition, a retrospective pharmacovigilance study was conducted using the Food and Drug Administration (FDA) Adverse Events System database. Reporting odds ratio (ROR) and Bayesian information components (IC) were used to perform the disproportionality analysis. Cases were extracted from January 2011 to September 2020. We identified 381 (20.24%) maculopapular rash, 213 (11.32%) vitiligo, 215 (11.42%) Stevens‐Johnson syndrome (SJS), and 165 (8.77%) toxic epidermal necrolysis (TEN) cases. For vitiligo, anti-PD-1/L1 combined with anti-CTLA-4 therapy showed the strongest signal (ROR: 55.89; 95% CI: 42.34–73.78; IC025: 4.73). Palmar-plantar erythrodysesthesia (PPE) was reported with the most significant association with combined anti-PD-1/L1 and VEGF (R)-TKIs (ROR: 18.67; 95% CI: 14.77–23.60; IC025: 3.67). For SJS/TEN, antiPD-1 inhibitors showed the strongest signal (ROR: 3.07; 95% CI: 2.68–3.52; IC025: 1.39). The median onset time of vitiligo and SJS/TEN was 83 and 24 days, respectively.Conclusion: Overall, in selected cutaneous AEs, each of them showed specific characteristics. It is necessary to realize their differences and take appropriate interventions in patients with different regimens.
- 2 June 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1076473
Open AccessSelected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis
Introduction: Cutaneous adverse events are commonly reported immune-related adverse events (irAEs), some of which are serious or even life-threatening, and it is essential to study these specific cutaneous AEs to understand their characteristics and risk.Methods: We performed a meta-analysis of published clinical trials for immune checkpoint inhibitors (ICIs) to evaluate the incidence of cutaneous adverse events, using data from PubMed, Embase, and the Cochrane Library databases.Results: A total of 232 trials with 45,472 patients were involved. Results showed that anti-PD-1 and targeted therapy combinations were associated with higher risk for most of the selected cutaneous adverse events. In addition, a retrospective pharmacovigilance study was conducted using the Food and Drug Administration (FDA) Adverse Events System database. Reporting odds ratio (ROR) and Bayesian information components (IC) were used to perform the disproportionality analysis. Cases were extracted from January 2011 to September 2020. We identified 381 (20.24%) maculopapular rash, 213 (11.32%) vitiligo, 215 (11.42%) Stevens‐Johnson syndrome (SJS), and 165 (8.77%) toxic epidermal necrolysis (TEN) cases. For vitiligo, anti-PD-1/L1 combined with anti-CTLA-4 therapy showed the strongest signal (ROR: 55.89; 95% CI: 42.34–73.78; IC025: 4.73). Palmar-plantar erythrodysesthesia (PPE) was reported with the most significant association with combined anti-PD-1/L1 and VEGF (R)-TKIs (ROR: 18.67; 95% CI: 14.77–23.60; IC025: 3.67). For SJS/TEN, antiPD-1 inhibitors showed the strongest signal (ROR: 3.07; 95% CI: 2.68–3.52; IC025: 1.39). The median onset time of vitiligo and SJS/TEN was 83 and 24 days, respectively.Conclusion: Overall, in selected cutaneous AEs, each of them showed specific characteristics. It is necessary to realize their differences and take appropriate interventions in patients with different regimens.